Priovant Therapeutics
brepocitinib
dermatomyositis
Countdown
86days
FDA decision · ~ Sep 30, 2026 estimated
What's at stake
The FDA's approval decision on brepocitinib for dermatomyositis is due ~ Sep 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 12h ago
“The U.S. Food and Drug Administration has granted the NDA Priority Review.”